ClinicalTrials.gg
RecruitingNCT06455956GH-miRNA2Updated Jun 13, 2024

Use of miRNAs in Growth Hormone Deficiency (GHD)

An observational study in Growth Hormone Deficiency, sponsored by University of Parma. Recruiting at 1 site in Italy. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by University of Parma · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Dwarfism, Pituitary with a site in Italy — 2 open to participants now, 2 under way, none of them phase 3. Dwarfism, Pituitary · Italy.

Started
2023
with 1 other
Observational
8 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies in Dwarfism, Pituitary with a site in Italy, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 27th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

2 of the 28 studies in Dwarfism, Pituitary with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Dwarfism, Pituitary with a site in Italy, or all of them as a file.
02

Study summary

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Read the detailed description

In 200 prepubertal and pubertal subjects with the suspicion of GHD, the levels of three specific circulating miRNas will be measured to establish whether they can be used for the diagnosis of GH deficiency. In subjects with isolated idiopathic GHD (IIGHD), short statured patients born SGA, Noonan and Turner syndromes, and SHOX deficiency, we will also assess the changes of the identified miRNAs before and after 3 months on GH therapy to verify an early growth prediction model for growth response at 12 months on treatment. Finally, we plan to identify any differences in these miRNAs at 3 months on treatment using daily GH versus weekly (long-acting) GH.

03

Conditions studied

  • Growth Hormone Deficiency

Keywords

  • growth hormone
  • miRNA
  • growth hormone deficiency
  • growth hormone treatment
  • small for gestational age
  • Turner syndrome
  • Noonan syndrome
  • SHOX deficiency
04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients will be investigated in routine practice during the normal workup for short stature and stunted growth. Treatment will be also delivered accordind to standard care indications and as established by regulatory agencies in Italy.

Eligibility criteria

Inclusion Criteria for aim 1:

  • Children with short stature and suspicion of GHD
  • Subjects with organic GH deficiency

Exclusion criteria for aim 1:

-Subjects with underlying genetic conditions and chronic diseases

Inclusion Criteria for aim 2-3-5:

  • patients having confirmed GHD enrolled for aim 1
  • patients with growth failure and born SGA (>4 yr of age)
  • patients with Noonan and Turner syndrome and growth failure
  • patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure

Inclusion Criteria for aim 4:

  • Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Assessing new biomarkers for the diagnosis of GHD

    The 1st objective will consist in the enrolment of 200 subjects, nationwide, undergoing standard routine work-up for the diagnosis of GHD. The specific miRNAs will be measured at the time of both stimulation tests in order to include subjects with both confirmed and unconfirmed GHD and guarantee reproducibility; in addition, subjects with organic GH deficiency will be included.

    Time frame: 3 years

  2. Measuring miRNA changes after 3 months on GH therapy

    The 2nd objective will consist in measuring these specific miRNAs before and at 3 months on treatment in 200 subjects with isolated idiopathic GHD(IIGHD), and in 60 short statured patients born SGA, in 60 having Noonan and Turner syndromes, and in 30 with SHOX deficiency, according to current indications to verify whether changes are confirmed in pubertal versus prepubertal subjects and in conditions other than IIGHD.

    Time frame: 3 years

  3. Multiple linear regression models

    The 3rd objective will consist in investigating the major determinants of height variations between 0 and 6 months, 0 and 12 months and the variance of growth rate variation between 0 and 6 months including the levels and/or changes in the specific miRNAs at baseline and at 3 months on treatment by using multiple linear regression models to establish early prediction models of growth response..

    Time frame: 3 years

  4. Measuring miRNA changes between daily and long-acting GH therapy

    The 4th objective will consist in measuring these specific miRNAs before and at 3 months on treatment in children with IIGHD being treated with daily versus longacting GH. Findings will be compared with those in the IIGHD group receiving daily GH treatment as an exploratory task, thus, only a small number of subjects will be enrolled, and anyway as many as possible.

    Time frame: 3 years

Secondary outcomes

  1. Sex-specific miRNA changes after 3 months on long-acting GH therapy

    Any differences between males and females in miRNAs expression after 3 months of long-acting GH therapy will be evaluated.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2025, 23 months after the start.

Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 13, 2024
StartActual
Apr 13, 2023
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 1, 2026
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06455956
Lead sponsor
University of Parma
Collaborators
Azienda Ospedaliera Universitaria Policlinico "G. Martino", Ospedali Riuniti Ancona, Federico II University, Azienda Unita Sanitaria Locale di Piacenza, Azienda Ospedaliero Universitaria Policlinico Modena, Azienda USL Reggio Emilia - IRCCS, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Ospedali Riuniti di Foggia, IRCCS Ospedale San Raffaele, Università degli Studi del Piemonte Orientale Amedeo Avogadro, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto Auxologico Italiano, OSPEDALE CARLO POMA ASST MANTOVA, University of Campania Luigi Vanvitelli, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Responsible party
Sponsor
First posted
Jun 13, 2024
Start date
Apr 13, 2023
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Jun 13, 2024

Study contacts

Maria E Street, MD, PhD
Contact
mariaelisabeth.street@unipr.it
+39 0521 033557
Maria E Street, MD, PhD
principal investigator · University of Parma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion